Coramitug is well tolerated and leads to a statistically significant reduction in N-terminal pro-brain type natriuretic peptide (NT-proBNP)—a marker of disease progression in transthyretin-mediated ...

While there is currently no cure, pharmacological therapies for progressive pulmonary fibrosis (PPF) include immunomodulatory agents that aim to reduce inflammation and antifibrotics that delay ...

Awareness of the key symptoms of NF1 can help in early diagnosis. A young male patient was diagnosed with neurofibromatosis type 1 (NF1) after undergoing detailed clinical investigations, according to ...

The combination strategy of LXH254 and trametinib effectively overcame adaptive and acquired resistance to MEK inhibition. Combined inhibition of B/CRAF and mitogen-activated extracellular ...

Ivabradine treatment slowed resting heart rate and reduced the levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in some patients with ATTR. MINNEAPOLIS—The sodium channel ...

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...

The mean gestational age at delivery was significantly higher in the late intrauterine transfusion group than in the early intrauterine transfusion group (P .001). Late intrauterine blood transfusions ...

Patients with autoimmune nodopathy more frequently had blood–cerebrospinal fluid barrier dysfunction and total intrathecal immunoglobulin G synthesis than patients with chronic inflammatory ...

The potential of vitamin D as an add-on therapy lies in its immunomodulatory effect on T cell-mediated and humoral immune responses, complement activation, cytokines, and inflammasomes. Vitamin D ...

Kerrie Walters, who has MS, and her service dog, Wooldridge, at home in Grants Pass, Oregon (Credit: Jennifer Butler Photography) Kerrie Walters first heard of PoNS in a chance encounter with TV ...

More than half (52.4%) of the patients had target joints, with the mean number per patient ranging from 1.3 to 2.3, irrespective of hemophilia type or inhibitor status. In general, patients receiving ...

In CIDP, SOC therapies (immunoglobulins/corticosteroids) are burdensome, have variable efficacy, and significant side-effects. Two phase 3 clinical trials, MOBILIZE ...